Contact our breast care nurses 0808 800 6000

Breast Cancer Now media statements

149 results
We respond to draft NICE decision to not recommend tucatinib with trastuzumab and capecitabine for routine use on the NHS

The National Institute for Health and Care Excellence (NICE) has today (Tuesday 26 October 2021) announced its provisional decision to not recommend breast cancer treatment tucatinib with trastuzumab and capecitabine for routine use on the NHS in England for treating HER2 positive, locally advanced or secondary breast cancer after at least two prior anti-HER2 treatment regimens.

26 Oct 2021